ChAdOx1 nCoV-19疫苗接种后血小板减少与多发血栓一例
报告一例既往健康的30岁女性在接种ChAdOx1 nCoV-19疫苗后第二周出现血小板减少、瘀斑、门静脉血栓和脑静脉窦血栓。检查发现凝血酶原基因突变杂合子及长期口服避孕药使用史,4T HIT评分最高且抗PF4/肝素抗体免疫检测阳性,提示自身免疫性HIT为潜在机制。作者强调临床警惕,建议将此视为疫苗诱导免疫性血栓性血小板减少症。
要点
- 接种ChAdOx1 nCoV-19疫苗后第二周出现血小板减少伴多发血栓需警惕。
- 4T HIT评分最高且抗PF4/肝素抗体阳性提示自身免疫性HIT机制。
- 短期多发血栓伴血小板减少和消耗性凝血病模式高度不寻常。
核心结论
- 本病例强调接种ChAdOx1 nCoV-19疫苗后血小板减少和多发血栓的临床警惕性,建议视为疫苗诱导免疫性血栓性血小板减少症,但因果关系尚未确立。
研究设计与样本
- 单例病例报告:一名既往健康的30岁女性,接种ChAdOx1 nCoV-19疫苗后第二周发病。
主要发现
- 患者出现血小板减少、瘀斑、门静脉血栓和脑静脉窦血栓。
- 易栓症检查显示凝血酶原突变杂合子,无骨髓增殖性肿瘤、感染或自身免疫病证据。
- 唯一暂时性危险因素为长期口服避孕药使用。
- 4T HIT评分为最高分,抗血小板因子4/肝素抗体免疫检测阳性。
关键数值与推荐
- 4T HIT评分为最高分。
- 抗血小板因子4/肝素抗体免疫检测阳性。
临床怎么用
- 对接种ChAdOx1 nCoV-19疫苗后出现血小板减少和多发血栓的患者应提高临床警惕。
- 可评估4T HIT评分及抗血小板因子4/肝素抗体以识别潜在自身免疫性HIT机制。
局限性
- 单例病例报告,因果关系尚未确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recently, reports of severe thromboses, thrombocytopenia, and hemorrhage in persons vaccinated with the chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19, AZD1222, Vaxzevria; Oxford/AstraZeneca) against severe acute respiratory syndrome coronavirus 2 have emerged. We describe an otherwise healthy 30-year-old woman who developed thrombocytopenia, ecchymosis, portal vein thrombosis, and cerebral venous sinus thrombosis the second week after she received the ChAdOx1 nCoV-19 vaccine. Extensive diagnostic workup for thrombosis predispositions showed heterozygosity for the prothrombin mutation, but no evidence of myeloproliferative neoplasia or infectious or autoimmune diseases. Her only temporary risk factor was long-term use of oral contraceptive pills (OCPs). Although both the prothrombin mutation and use of OCPs predispose to portal and cerebral vein thrombosis, the occurrence of multiple thromboses within a short time and the associated pattern of thrombocytopenia and consumption coagulopathy are highly unusual. A maximum 4T heparin-induced thrombocytopenia (HIT) score and a positive immunoassay for anti-platelet factor 4/heparin antibodies identified autoimmune HIT as a potential pathogenic mechanism. Although causality has not been established, our case emphasizes the importance of clinical awareness. Further studies of this potentially new clinical entity have suggested that it should be regarded as a vaccine-induced immune thrombotic thrombocytopenia.
引用
- Tølbøll Sørensen AL, Rolland M, Hartmann J, et al. A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2. Blood Adv. 2021. PMID: 34137813. doi:10.1182/bloodadvances.2021004904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。